Japan Launches ‘Safety Net’ Initiative As PMDA Looks To Resolve Drug Lag With The West (part 1 of 2)
This article was originally published in The Pink Sheet Daily
Executive Summary
Risk management program follows drug from first-in-human to post-market, gathering safety data.
You may also be interested in...
East Asian Regulators Collaborate To Reduce Drug Lags (Part 2 of 2)
[Editor's note: This is part two of a two-part story. The first part appeared in PharmAsia News, April 17, 2008.]
Japan’s MHLW Steps Up Efforts To Reduce Drug Approval Lag Time
TOKYO - On the back of rising pressures, Japan's Ministry of Health, Labor and Welfare is stepping up efforts to shorten new drug approval periods that now are woefully behind other countries - yet finds the undertaking a tall task that may take longer than officials envisioned
Japan’s 2014 Drug Price Reforms Extend Price Premium Program
The Japanese government has decided to revise its drug pricing policies starting in April 2014. Changes include extending a price premium program for two more years, bundling the pricing of similar generic drugs, and reduced pricing on long-listed drugs.